| 0 |
FOSTER CARE |
1 |
0.0909 |
| 1 |
CATHETER SITE DRYNESS |
1 |
0.0256 |
| 2 |
PEPTOSTREPTOCOCCUS INFECTION |
1 |
0.0095 |
| 3 |
APPLICATION SITE HAEMATOMA |
1 |
0.0055 |
| 4 |
DEAFNESS PERMANENT |
1 |
0.0051 |
| 5 |
MEIBOMIAN GLAND DYSFUNCTION |
1 |
0.0022 |
| 6 |
METAPNEUMOVIRUS INFECTION |
1 |
0.0013 |
| 7 |
ENDOCRINE OPHTHALMOPATHY |
1 |
0.0012 |
| 8 |
RIGHT VENTRICULAR DYSFUNCTION |
1 |
0.0009 |
| 9 |
STENOTROPHOMONAS INFECTION |
1 |
0.0007 |
| 10 |
PARAINFLUENZAE VIRUS INFECTION |
1 |
0.0007 |
| 11 |
HYPOREFLEXIA |
1 |
0.0005 |
| 12 |
APPLICATION SITE SCAB |
1 |
0.0005 |
| 13 |
APPLICATION SITE SWELLING |
2 |
0.0004 |
| 14 |
DIABETIC COMPLICATION |
1 |
0.0004 |
| 15 |
OXYGEN SATURATION ABNORMAL |
1 |
0.0004 |
| 16 |
ADENOVIRUS INFECTION |
1 |
0.0003 |
| 17 |
BREAST CANCER RECURRENT |
1 |
0.0003 |
| 18 |
INJECTION SITE INFECTION |
1 |
0.0003 |
| 19 |
PRODUCT CONTAMINATION |
1 |
0.0003 |
| 20 |
CATHETER SITE INFECTION |
1 |
0.0003 |
| 21 |
RHINOVIRUS INFECTION |
1 |
0.0003 |
| 22 |
ABDOMINAL ABSCESS |
1 |
0.0002 |
| 23 |
DERMATITIS CONTACT |
2 |
0.0002 |
| 24 |
SENSITIVE SKIN |
1 |
0.0001 |
| 25 |
CEREBRAL DISORDER |
1 |
0.0001 |
| 26 |
PAROSMIA |
1 |
0.0001 |
| 27 |
PSEUDOMONAS INFECTION |
1 |
0.0001 |
| 28 |
SKIN SWELLING |
1 |
0.0001 |
| 29 |
RESPIRATORY SYNCYTIAL VIRUS INFECTION |
1 |
0.0001 |
| 30 |
PRODUCT COMMUNICATION ISSUE |
1 |
0.0001 |
| 31 |
PRODUCT DISTRIBUTION ISSUE |
1 |
0.0001 |
| 32 |
RENAL PAIN |
1 |
0.0001 |
| 33 |
BLOOD CALCIUM DECREASED |
1 |
0.0001 |
| 34 |
SCAB |
1 |
0.0001 |
| 35 |
GLOMERULAR FILTRATION RATE DECREASED |
1 |
0.0001 |
| 36 |
INJECTION SITE DISCOLOURATION |
1 |
0.0001 |
| 37 |
APPLICATION SITE ERYTHEMA |
2 |
0.0001 |
| 38 |
ORAL CANDIDIASIS |
1 |
0.0001 |
| 39 |
TOOTH INFECTION |
1 |
0.0001 |
| 40 |
APPLICATION SITE RASH |
1 |
0.0001 |
| 41 |
SKIN REACTION |
1 |
0.0001 |
| 42 |
SINUS TACHYCARDIA |
1 |
0.0001 |
| 43 |
IMPAIRED QUALITY OF LIFE |
1 |
0.0001 |
| 44 |
PRODUCT USE COMPLAINT |
1 |
0.0001 |
| 45 |
BACTERIAL INFECTION |
1 |
0.0001 |
| 46 |
ACUTE RESPIRATORY FAILURE |
1 |
0.0001 |
| 47 |
BLOOD PRESSURE SYSTOLIC INCREASED |
1 |
0.0001 |
| 48 |
FEEDING DISORDER |
1 |
0.0000 |
| 49 |
APPLICATION SITE PAIN |
1 |
0.0000 |
| 50 |
NEURALGIA |
1 |
0.0000 |
| 51 |
INJECTION SITE RASH |
1 |
0.0000 |
| 52 |
DEVICE USE ERROR |
1 |
0.0000 |
| 53 |
WRONG TECHNIQUE IN DRUG USAGE PROCESS |
1 |
0.0000 |
| 54 |
PRODUCT QUALITY ISSUE |
3 |
0.0000 |
| 55 |
NEPHROLITHIASIS |
1 |
0.0000 |
| 56 |
TINNITUS |
1 |
0.0000 |
| 57 |
UPPER RESPIRATORY TRACT INFECTION |
1 |
0.0000 |
| 58 |
RENAL DISORDER |
1 |
0.0000 |
| 59 |
RASH ERYTHEMATOUS |
1 |
0.0000 |
| 60 |
CELLULITIS |
1 |
0.0000 |
| 61 |
DRUG EFFECT DECREASED |
1 |
0.0000 |
| 62 |
NECK PAIN |
1 |
0.0000 |
| 63 |
ASTHMA |
2 |
0.0000 |
| 64 |
VERTIGO |
1 |
0.0000 |
| 65 |
DISCOMFORT |
1 |
0.0000 |
| 66 |
INJECTION SITE ERYTHEMA |
2 |
0.0000 |
| 67 |
DEEP VEIN THROMBOSIS |
1 |
0.0000 |
| 68 |
DEVICE DIFFICULT TO USE |
1 |
0.0000 |
| 69 |
INJECTION SITE REACTION |
1 |
0.0000 |
| 70 |
BURNING SENSATION |
1 |
0.0000 |
| 71 |
THERAPEUTIC PRODUCT EFFECT INCOMPLETE |
1 |
0.0000 |
| 72 |
DYSGEUSIA |
1 |
0.0000 |
| 73 |
DRUG DOSE OMISSION BY DEVICE |
1 |
0.0000 |
| 74 |
ADVERSE EVENT |
1 |
0.0000 |
| 75 |
BREAST CANCER |
1 |
0.0000 |
| 76 |
SWELLING |
1 |
0.0000 |
| 77 |
PULMONARY EMBOLISM |
1 |
0.0000 |
| 78 |
MIGRAINE |
1 |
0.0000 |
| 79 |
ILLNESS |
1 |
0.0000 |
| 80 |
WHITE BLOOD CELL COUNT DECREASED |
1 |
0.0000 |
| 81 |
INFLUENZA |
1 |
0.0000 |
| 82 |
MUSCULAR WEAKNESS |
1 |
0.0000 |
| 83 |
PYREXIA |
3 |
0.0000 |
| 84 |
BACK PAIN |
2 |
0.0000 |
| 85 |
EMOTIONAL DISTRESS |
1 |
0.0000 |
| 86 |
VISUAL IMPAIRMENT |
1 |
0.0000 |
| 87 |
HEADACHE |
5 |
0.0000 |
| 88 |
DRY SKIN |
1 |
0.0000 |
| 89 |
NEUTROPENIA |
1 |
0.0000 |
| 90 |
VISION BLURRED |
1 |
0.0000 |
| 91 |
PRODUCT DOSE OMISSION ISSUE |
2 |
0.0000 |
| 92 |
HYPOAESTHESIA |
1 |
0.0000 |
| 93 |
BLOOD PRESSURE INCREASED |
1 |
0.0000 |
| 94 |
INJECTION SITE PAIN |
2 |
0.0000 |
| 95 |
PARAESTHESIA |
1 |
0.0000 |
| 96 |
MYOCARDIAL INFARCTION |
1 |
0.0000 |
| 97 |
COVID-19 |
1 |
0.0000 |
| 98 |
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION |
1 |
0.0000 |
| 99 |
MUSCLE SPASMS |
1 |
0.0000 |
| 100 |
CHEST PAIN |
1 |
0.0000 |
| 101 |
PRODUCT USE ISSUE |
1 |
0.0000 |
| 102 |
ANAEMIA |
1 |
0.0000 |
| 103 |
PAIN |
3 |
0.0000 |
| 104 |
ERYTHEMA |
1 |
0.0000 |
| 105 |
DIARRHOEA |
3 |
0.0000 |
| 106 |
WEIGHT INCREASED |
1 |
0.0000 |
| 107 |
VOMITING |
2 |
0.0000 |
| 108 |
FEELING ABNORMAL |
1 |
0.0000 |
| 109 |
NAUSEA |
3 |
0.0000 |
| 110 |
DYSPNOEA |
2 |
0.0000 |
| 111 |
ANXIETY |
1 |
0.0000 |
| 112 |
PAIN IN EXTREMITY |
1 |
0.0000 |
| 113 |
PRURITUS |
1 |
0.0000 |
| 114 |
ARTHRALGIA |
1 |
0.0000 |
| 115 |
DEATH |
2 |
0.0000 |
| 116 |
RASH |
1 |
0.0000 |
| 117 |
DRUG INEFFECTIVE |
2 |
0.0000 |
| 118 |
OFF LABEL USE |
1 |
0.0000 |